Trial intelligence / Profile preview

Zanubrutinib + short-course bendamustine + CD20 antibody in treatment-naïve Waldenström's macroglobulinemia

ChiCTR2500113199Phase 2Not yet recruiting

Sponsor: Institute of Hematology and Blood Diseases Hospital
Start: Nov 2025
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of zanubrutinib in Waldenström macroglobulinemia (WM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Best deep response rate (≥VGPR). Planned start Nov 2025; status: not yet recruiting.

Drugs

zanubrutinib

Conditions

Waldenström macroglobulinemia (WM)

Beyond the preview

Go deeper on ChiCTR2500113199.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2500113199.